ProCE Banner Activity

How We Are Integrating New Findings Into Treatment for HER2-Positive Breast Cancer

Clinical Thought
In this commentary, 2 oncologists, an oncology nurse, and a pharmacist discuss how recent data on HER2-targeted treatment are changing the therapeutic paradigm in early and metastatic breast cancer.

Released: May 10, 2022

Expiration: May 09, 2023

Share

Faculty

Aditya Bardia

Aditya Bardia, MD, MPH, FASCO

Program Director, Breast Medical Oncology
Assistant Chief (Translational Research), Division of Hematology-Oncology
Professor of Medicine, Geffen School of Medicine, University of California Los Angeles
Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Center
Los Angeles, California

Kayla Douglas

Kayla Douglas, PharmD

Director of Pharmacy
Mississippi Center for Advanced Medicine
Madison, Mississippi

Sara Hurvitz

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Danielle Roman

Danielle Roman, PharmD, BCOP

Manager, Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Puma Biotechnology, Inc.

Seagen Inc.

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Aditya Bardia, MD, MPH, FASCO

Program Director, Breast Medical Oncology
Assistant Chief (Translational Research), Division of Hematology-Oncology
Professor of Medicine, Geffen School of Medicine, University of California Los Angeles
Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Center
Los Angeles, California

Aditya Bardia, MD, MPH, has disclosed that he has received consultant/advisor/speaker fees from AstraZeneca, Daiichi Pharma, Foundation Medicine, Genentech, Gilead Sciences, Immunomedics, Lilly, Merck, Novartis, Pfizer, Phillips, Radius Health, and Sanofi and funds for research support from AstraZeneca, Daiichi Pharma, Genentech, Gilead Sciences, Immunomedics, Lilly, Merck, Novartis, Pfizer, Radius Health, and Sanofi.

Kayla Douglas, PharmD

Director of Pharmacy
Mississippi Center for Advanced Medicine
Madison, Mississippi

Kristi Kay Orbaugh, MSN, NP, AOCNP, has disclosed that she has been a speaker for AstraZeneca, Bristol-Myers Squibb, DSI, Gilead Sciences, Lilly, MorphoSys, Pfizer, Regeneron, and Sanofi.

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Sara Hurvitz, MD, FACP, has disclosed that she has received funds for research support from Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, CytomX, Daiichi-Sankyo, Dignitana, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Immunomedics, Lilly, MacroGenics, Novartis, OBI Pharma, Orinove, Pfizer, Phoenix Molecular Designs, Pieris, PUMA, Radius, Sanofi, Seattle Genetics/Seagen, and Zymeworks.

Danielle Roman, PharmD, BCOP

Manager, Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania

Danielle Roman, PharmD, BCOP, has no relevant conflicts of interest to report.